Mirvaso Gel (Brimonidine 0.33%)

Mirvaso is the new FDA approved treatment from Galderma that was previously known as Sansrosa, CD07805/47 and Col-118. Mirvaso is the only topical treatment officially approved for the relief of the red face of rosacea. Mirvaso is Brimonidine Topical Gel 0.33% and is available in 30g and 45g tubes, on prescription only. It is used once per day and can last as long as 12 hours.

See below for Mirvaso User Reviews, news and updates

Recent Rosacea Blog Posts

Australia has the cheapest rosacea treatments in the world!

Being a rosacea sufferer in Australia can be a depressing experience. It seems that the rest of the English speaking world get all the latest and greatest treatments years before we do here downunder. New treatments can take years to be approved in Australia. We Ozzies suffer from a bit of an insecurity complex because […]

Continue Reading

Finacea vs. Metrogel and Mirvaso–Fight!

A recently listed Clinical Trial aims to recruit rosacea sufferers to find out how well they are getting on with their usage of Finacea, Metrogel and Mirvaso. The trial outcomes are several, but include the recording of adverse reactions to treatments, patient satisfaction and likelihood of switching rosacea treatment. The trial is being sponsored by […]

Continue Reading

Its official–Mirvaso, Soolantra and Oracea make the grade as proven rosacea treatments

The just published update to the 2011 Cochrane review of interventions for rosacea has given its opinion on the last 4 years of published rosacea research. Previous Cochrane reviews on rosacea interventions have been published in 2004, 2005 and 2011. This review looked at 106 randomized clinical trials with 13,631 participants. Cochrane Review Results The […]

Continue Reading

A really interesting paragraph from Dr. Powell in the September 2015 BJD. Understanding rosacea, Powell F.C., British Journal of Dermatology (2015) 173, pp635–640 Brimonidine tartrate gel 0.5%, a topical alpha 2 adrenergic agonist with vasoconstrictor properties, was shown to be effective in reducing moderate to severe erythema in patients with rosacea, a major benefit for […]

Continue Reading

Compensatory Flushing with Mirvaso: JAMA Dermatology

LEFT: Patient at initial clinic visit after 7 months of brimonidine treatment showing compensatory vasodilation and flushing in untreated areas of right lateral cheek and chest. RIGHT: Patient 1 week after cessation of brimonidine treatment showing marked improvement in compensatory vasodilation and flushing. A brief observation published in the Journal of American Medical Association Dermatology […]

Continue Reading

 

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.